Looking to quit smoking? Nabi Biopharmaceuticals may have just the thing to help. The company has successfully completed a Phase IIb trial of NicVax, which is being developed to treat nicotine addiction and prevent smoking relapse. According to data the company presented at a meeting of the American Heart Association, significant trends were seen at twelve months for both smoking cessation and long-term smoking abstinence. Dr. Leslie Hudson, Interim President and CEO of Nabi, said that the company will use the data to continue its hunt for a partner on the drug.
- see this release from Nabi